PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

High Grade Glioma Clinical Trial

Official title:

Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05096481
• Other study ID #: CONNECT1906
• Secondary ID: R01FD007283
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 15, 2024
• Est. completion date: June 15, 2030

Study information

• Verified date: May 2024
• Source: Nationwide Children's Hospital
• Contact: Leonie Mikael, PhD
• Phone: 6147223284
• Email: LEONIE.MIKAEL[@]NATIONWIDECHILDRENS.ORG
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB).

PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51.

Funding Source - FDA OOPD

Description:

This phase II clinical trial will have 3 strata in order to assess the efficacy of a highly immunogenic CMV-directed peptide vaccines in children with (1) recurrent medulloblastoma (rMB), (2) newly-diagnosed high-grade gliomas (HGG) and (3) newly-diagnosed diffuse intrinsic pontine glioma (DIPG). Each stratum will run independently with a different endpoint and statistical design.

Within each stratum, the populations that may be used for analysis are defined as:

• Safety Analysis: Patients who receive at least 1 dose of the treatment will be used for safety analyses.

• Efficacy Analysis: Patients who receive at least 1 dose of the treatment will be used for efficacy analyses.

Stratum I: Patients with recurrent medulloblastoma with measurable disease (see eligibility) can be enrolled at any point following recurrence regardless of any prior therapy. For the purpose of this study, recurrence will be defined as a new lesion confirmed by biopsy or resection, positive cerebrospinal fluid (CSF) cytology, or recurrent/progressive tumor on MRI.

Strata II and III: Patients with newly-diagnosed high-grade glioma or DIPG may be enrolled any time within 42 days after completing radiation.

Cycle 1 (Induction cycle) is 77±2 days. Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1 and receive PEP-CMV vaccine intradermally at dose level 1 (250 μg/m2 ) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle which is 77 ± 2 days, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered intradermally every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days for a total of 24 cycles.

Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.

The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Est. completion date: June 15, 2030
• Est. primary completion date: June 15, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 25 Years

Eligibility

Inclusion Criteria for patients with recurrent /progressive medulloblastoma (stratum I)

1. Age: Patients must be =3 and =25 years of age at the time of study enrollment

2. Diagnosis: Recurrent medulloblastoma: Patients must have a diagnosis of medulloblastoma that is recurrent, progressive or refractory. All patients must have histological verification of a medulloblastoma, at original diagnosis or relapse.

• Patients must have adequate pretrial tumor material available

• Patients must have measurable disease defined as a lesion that can be measured in two perpendicular diameters on MRI.

3. Metastatic Disease: Patients with M+ disease are eligible.

4. Performance Status:

Karnofsky = 50% for patients >16 years of age or Lansky = 50 for patients = 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score. See Appendix I.

Adequate neurologic function defined as:

• Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to enrollment.

• Patients with current seizure disorders may be enrolled if seizures are well-controlled on antiepileptic therapies.

5. Prior Therapy:

1. Radiotherapy: prior radiotherapy requirements Patients must have received prior disease-directed therapy including radiotherapy for their initial diagnosis of medulloblastoma unless patients are less than 4 years of age at the time of enrollment.

For those less than 4 years of age at the time of enrollment, prior disease directed therapy does not have to include prior radiotherapy.

Patients must have had their last fraction of:

• Craniospinal irradiation, total body irradiation or radiation to = 50% of pelvis > 3 months prior to enrollment.

• Focal irradiation > 4 weeks prior to enrollment

2. Myelosuppressive anticancer therapy: Patients must have received their last dose of myelosuppressive anticancer therapy at least 21 days prior to enrollment

3. Immunotherapy: Patients must have received their last dose of any immunotherapy agents at least 30 days prior to enrollment

4. Non-myelosuppressive anticancer agents: Patients must have received their last dose of non-myelosuppressive anticancer agents at least 7 days prior to study enrollment.

5. Antibodies: Patients must have received their last dose of any antibodies at least 21 days prior to enrollment.

6. Hematopoietic growth factors: Patients must have received their last dose of hematopoietic growth factors at least 14 days prior to enrollment for a long-acting growth factor (e.g. pegfilgrastim) or 7 days prior to enrollment for short-acting growth factor.

7. Autologous stem cell infusion: At least 90 days must have elapsed after an autologous stem cell infusion

6. Organ Function Requirements:

1. Adequate bone marrow function defined as:

• ANC (Absolute neutrophil count) = 1000/µl.

• Platelets = 75,000/µl.

• Hemoglobin > 8 g/dL. (may be supported)

2. Adequate Renal Function defined as: Creatinine clearance or radioisotope GFR = 70ml/min/1.73 m2 or A serum creatinine based on age/gender as follows:

Age: Maximum Serum Creatinine (mg/dL)

• 2 to < 6 years: 0.8 (Male) 0.8 (Female)

• 6 to < 10 years: 1 (Male) 1 (Female)

• 10 to < 13 years: 1.2 (Male) 1.2 (Female)

• 13 to < 16 years: 1.5 (Male) 1.4 (Female)

• = 16 years: 1.7 (Male) 1.4 (Female)

3. Adequate Liver Function Defined as

• Total bilirubin =1.5 times institutional ULN

• AST(SGOT) =3 × institutional upper limit of normal

• ALT(SGPT) =3 × institutional upper limit of normal

4. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.

5. Signed informed consent according to institutional guidelines must be obtained prior to registration.

Inclusion Criteria for Patients with Newly-Diagnosed High-Grade Gliomas (HGG) (stratum II) and Newly-Diagnosed (DIPG) (stratum III)

1. Age: Patients must be =3 and =25 years of age at the time of study enrollment

2. Diagnosis

1. Stratum II: patients must have histologically confirmed, newly-diagnosed HGG (such as anaplastic astrocytoma, glioblastoma, H3K27M mutant diffuse midline glioma, etc.).

• Patients with a newly-diagnosed HGG must enroll within 6 weeks of their final dose of standard radiation therapy with or without chemotherapy.

• Patients with primary spinal cord tumors are eligible

2. Stratum III: Patients with a newly-diagnosed DIPG:

• Patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.

• Patients with brainstem lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of an infiltrating astrocytoma WHO grades II-IV.

3. Metastatic Disease: Patients with M+ disease are eligible.

4. Performance Status:

Karnofsky = 50 for patients > 16 years of age and Lansky = 50 for patients = 16 years of age (See Appendix I). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

Adequate neurologic function defined as:

• Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment.

5. Prior Therapy requirements: Patients must have received no prior therapy other than surgery, radiation, chemotherapy during radiotherapy and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy).

Patients with a newly diagnosed high-grade glioma or DIPG must enroll within 6 weeks of their final dose of standard of care radiation therapy with or without chemotherapy.

1. Patients with HGG or DIPG are permitted, but not required, to have received chemotherapy during radiation. Bevacizumab is permitted prior to enrollment in patients with DIPG or HGG. Patients must have received their last dose of bevacizumab at least 14 days prior to enrollment.

2. For HGG patients, Patients must have received radiotherapy at a standard dose of 54 Gy in 1.8 Gy fractions for approximately 6 weeks with an acceptable variance of 10%. Radiation therapy must have begun no later than 30 days after the date definitive surgery.

3. Patients must enroll within 42 days of their final dose of standard radiation therapy

4. For patients with DIPG, Patients must have received radiotherapy at a standard dose of radiotherapy of 54 Gy in 1.8 Gy daily fractions for approximately 6 weeks with an acceptable variance rate of 10%. Radiation therapy must have begun no later than 30 days after the date of radiographic diagnosis or biopsy

5. For patients with spinal cord HGG: Patients must have received radiotherapy at a standard dose of 54 Gy in 1.8 Gy fractions for approximately 6-7 weeks with an acceptable variance of 10%

6. For patients with metastatic disease: Patients may have received standard dose craniospinal therapy

6. Organ Function Requirements:

1. Adequate bone marrow function defined as

• ANC (Absolute neutrophil count) = 1000/µl.

• Platelets = 75,000/µl.

• Hemoglobin > 8 g/dL. (may be supported)

2. Adequate Renal Function defined as: Creatinine clearance or radioisotope GFR = 70ml/min/1.73 m2 or A serum creatinine based on age/gender as follows:

Age: Maximum Serum Creatinine (mg/dL)

• 2 to < 6 years: 0.8 (Male) 0.8 (Female)

• 6 to < 10 years: 1 (Male) 1 (Female)

• 10 to < 13 years: 1.2 (Male) 1.2 (Female)

• 13 to < 16 years: 1.5 (Male) 1.4 (Female)

• = 16 years: 1.7 (Male) 1.4 (Female)

3. Adequate Liver Function Defined as:

• Total bilirubin =1.5 times institutional ULN

• AST(SGOT) =3 × institutional upper limit of normal

• ALT(SGPT) =3 × institutional upper limit of normal

4. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.

5. Signed informed consent according to institutional guidelines must be obtained prior to registration.

Exclusion Criteria for all strata:

1. Pregnancy or Breast-Feeding:

1. Pregnant or breast-feeding women will not be entered on this study due to known or unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-monarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.

2. Pregnancy Prevention Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after drug cessation.

2. Study Specific:

1. Active infection requiring treatment

2. Patients with malignancy related to HIV or solid organ transplant: known history of HIV, HBV surface antigen positivity or positive HCV antibody are not eligible. Viral testing is not required unless clinically indicated in patients without a known history

3. Known immunosuppressive disease

4. Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or moderate to severe pulmonary problems generally defined by need for medical intervention (e.g., oxygen, medications) and/or limiting activities of daily living (generally CTCAE Grade 2 or higher) or shortness of breath with limited exertion are not eligible. Pulmonary conditions include (but are not limited to) COPD, asthma, and hemi-pneumectomy

5. Patients receiving concomitant immunosuppressive agents for medical conditions; inhaled corticosteroids for asthma are allowed.

6. Patients receiving concomitant tumor-directed therapy

7. Patients receiving any other investigational drug therapy.

8. Patients on dexamethasone > 0.1 mg/Kg/day up to maximum dose of 4 mg/day or equivalent.

9. Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction).

10. Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy

11. Patients at high risk for imminent neurologic decline due to extensive bulk disease, midline shift, or herniation on MRI. These patients should be discussed with the study chairs.

Related Conditions & MeSH terms

• Diffuse Intrinsic Pontine Glioma
• Glioma
• High Grade Glioma
• Medulloblastoma
• Recurrence
• Recurrent Medulloblastoma

Intervention

Biological:
• PEP-CMV
The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.

Drug:
• Temozolomide
Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1

Biological:
• Tetanus Diphtheria Vaccine
Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.

Locations

Country	Name	City	State
United States	Children's Hospital Colorado	Aurora	Colorado
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	Nationwide Children's Hospital	Columbus	Ohio
United States	Duke University Medical Center	Durham	North Carolina
United States	Texas Children's Hospital	Houston	Texas
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania
United States	Seattle Children's Hospital	Seattle	Washington
United States	Children's National Medical Center	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Nationwide Children's Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	4-mo PFS in patients with recurrent medulloblastoma	To determine the progression-free survival (PFS) at 4 months in pediatric or young adult patients with recurrent medulloblastoma treated with PEP-CMV.	4 months
Primary	1-yr OS in patients with newly diagnosed DIPG	To estimate the 1-year Overall Survival (OS) distribution in patients with newly diagnosed DIPG treated with radiotherapy followed by PEP-CMV	one year
Primary	1-yr PFS in patients with newly diagnosed HGG	To estimate the 1-year Progression Free Survival (PFS) distribution in patients with newly diagnosed HGG treated with radiotherapy followed by PEP-CMV	one year
Secondary	ORR in patients with recurrent medulloblastoma	To determine the objective response rate (ORR) = partial response (PR) + complete response (CR) in patients with recurrent medulloblastoma treated with PEP-CMV	From Day 1 of treatment through 30 days following end of protocol treatment
Secondary	PFS in patients with recurrent medulloblastoma	To determine the 1-year Progression Free Survival (PFS) in patients with recurrent Medulloblastoma treated with PEP-CMV.	one year
Secondary	OS in patients with newly diagnosed HGG by PEP-CMV	To determine the 2-year Overall Survival (OS) in patients newly diagnosed with HGG treated with PEP-CMV.	2 years